- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00751504
Quetiapine in the Treatment of Psychotic Depression - a Pilot Study
January 23, 2013 updated by: PD Dr. Christine Norra, MD, PhD, Ruhr University of Bochum
Atypical antipsychotics have been found not only to be beneficial in the treatment of psychotic disorders, but even for depressive symptoms in patients with schizophrenia.
Remarkably, preliminary data suggest that the atypical antipsychotic quetiapine has antidepressive properties.
Until now, there is limited knowledge concerning the efficacy of quetiapine in major depressive illness and especially in psychotic depression.
In our own clinical practice, several patients with psychotic depression were successfully treated with quetiapine as add-on therapy or as monotherapy.
On the background of that, the convincing effects of quetiapine in bipolar depression, single-case reports and pilot studies concerning its effectiveness in depressive mood states in psychotic disorders as well as our clinical experiences, it is to assume that a treatment with quetiapine over a 6 weeks period show similar effects in major depressive episode with psychotic features, i.e. psychotic depression.
In this pilot study we plan to investigate 20 patients with psychotic features of depression under treatment with quetiapine.
Study Overview
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
NRW
-
Bochum, NRW, Germany, 44791
- LWL University Hospital Bochum of the Ruhr-University Bochum
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- provision of written informed consent
- diagnosis of depression with psychotic features by DSM-IV (296.23, 296.33)
- females and males aged 18 to 65 years
- female patients of childbearing potential must be using a reliable method of contraception and have a negative pregnancy test at enrollment
- patients must be able to understand and comply with the requirements of the study
- MADRS score above 20 points
Exclusion Criteria:
- pregnancy or lactation
- any DSM-IV Axis I disorder not defined in the inclusion criteria or not in full remission
- patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others
- known intolerance or lack of response to quetiapine, as judged by the investigator
- use of any cytochrome P450 3A4 inhibitors in the 14 days preceding enrollment
- use of any cytochrome P450 inducers in the 14 days preceding enrollment
- thyroid-stimulating hormone (TSH) concentration more than 10% above the upper limit of the normal range at enrollment
- administration of a depot antipsychotic injection within one dosing interval before randomisation
- substance or alcohol dependence at enrollment, as defined by DSM-IV
- opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM-IV criteria within 4 weeks prior to enrollment
- medical conditions that would affect absorption, distribution, metabolism, or excretion of study treatment
- risk of transmitting human immunodeficiency virus (HIV) or hepatitis B via blood or other body fluids
- unstable or inadequately treated medical illness, as judged by the investigator
- patients with diabetes mellitus (DM)
- an absolute neutrophil count (ANC) < 1.5x10E9 per liter
- history of idiopathic orthostatic hypotension, or condition that would predispose to
- ECG considered to show clinically significant abnormalities at enrollment as determined by a cardiologist
- involvement in the planning and conduct of the study
- previous enrollment or randomisation of treatment in the present study
- any serious and unstable somatic illness that, in the opinion of the investigator, would be negatively affects by the study medication
- participation in another drug trial within 4 weeks prior to enrollment into this study
- patients with unsufficient knowledge of the German language
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
MADRS
Time Frame: 6 weeks
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Clinical laboratory evaluation
Time Frame: 6 weeks
|
6 weeks
|
|
Urinalysis
Time Frame: 6 weeks
|
6 weeks
|
|
ECG
Time Frame: 6 weeks
|
6 weeks
|
|
Physical and neurological examination
Time Frame: 6 weeks
|
6 weeks
|
|
Vital signs
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Georg Juckel, M.D., Ph.D., LWL University Hospital Bochum
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Adson DE, Kushner MG, Eiben KM, Schulz SC. Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depress Anxiety. 2004;19(2):121-6. doi: 10.1002/da.10137.
- Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005 Jul;162(7):1351-60. doi: 10.1176/appi.ajp.162.7.1351.
- Catapano-Friedman L. Effectiveness of quetiapine in the management of psychotic depression in an adolescent boy with bipolar disorder, mixed, with psychosis. J Child Adolesc Psychopharmacol. 2001 Summer;11(2):205-6. doi: 10.1089/104454601750284144. No abstract available.
- Khouzam HR. Treatment of depressive mood in schizophrenia with the atypical antipsychotic quetiapine. Depress Anxiety. 2000;11(2):80-2. doi: 10.1002/(sici)1520-6394(2000)11:23.0.co;2-7.
- Hidalgo J, Rico-Villademoros F, Calandre EP. An open-label study of quetiapine in the treatment of fibromyalgia. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):71-7. doi: 10.1016/j.pnpbp.2006.06.023. Epub 2006 Aug 4.
- Masan PS. Atypical antipsychotics in the treatment of affective symptoms: a review. Ann Clin Psychiatry. 2004 Jan-Mar;16(1):3-13. doi: 10.1080/10401230490281410.
- Padla D. Quetiapine resolves psychotic depression in an adolescent boy. J Child Adolesc Psychopharmacol. 2001 Summer;11(2):207-8. doi: 10.1089/104454601750284153. No abstract available.
- Sajatovic M, Mullen JA, Sweitzer DE. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry. 2002 Dec;63(12):1156-63. doi: 10.4088/jcp.v63n1211.
- Schulz SC. New antipsychotic medications: more than old wine and new bottles. Bull Menninger Clin. 2000 Winter;64(1):60-75.
- Wijkstra J, Lijmer J, Balk FJ, Geddes JR, Nolen WA. Pharmacological treatment for unipolar psychotic depression: Systematic review and meta-analysis. Br J Psychiatry. 2006 May;188:410-5. doi: 10.1192/bjp.bp.105.010470.
- Zarate CA Jr, Rothschild A, Fletcher KE, Madrid A, Zapatel J. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry. 2000 Mar;61(3):185-9. doi: 10.4088/jcp.v61n0307.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2008
Primary Completion (Actual)
July 1, 2012
Study Completion (Actual)
July 1, 2012
Study Registration Dates
First Submitted
September 11, 2008
First Submitted That Met QC Criteria
September 11, 2008
First Posted (Estimate)
September 12, 2008
Study Record Updates
Last Update Posted (Estimate)
January 24, 2013
Last Update Submitted That Met QC Criteria
January 23, 2013
Last Verified
January 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mood Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Bipolar and Related Disorders
- Depression
- Depressive Disorder
- Psychotic Disorders
- Mental Disorders
- Bipolar Disorder
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Antidepressive Agents
- Quetiapine Fumarate
Other Study ID Numbers
- D1443L00040
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.